Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2020HaematologicaOpen Access

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

View Full Paper
Ask AI
Bookmark
Share

Authors

CTConstantine S. TamThe Alfred HospitalTRTadeusz RobakCopernicus Memorial HospitalPGPaolo GhiaVita-Salute San Raffaele University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tam et al. (2020) studied this question.

synapsesocial.com/papers/6a7e064e3fa445558d7d8f89https://doi.org/10.3324/haematol.2020.259432
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study2011 · 131 citations
  2. 2Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase2019 · 364 citations
  3. 3Toxicity and response criteria of the Eastern Cooperative Oncology Group1982 · 11,818 citations
  4. 4Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial2015 · 1,299 citations
  5. 5ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2020 · 83 citations